https://gi254023xinhibitor.com..../elements-from-the-n
Our results confirm the worthiness of maintaining angiogenesis inhibition with FOLFIRI-aflibercept in mCRC after development to a first-line therapy with bevacizumab. The introduction of hypertension during treatment is a potential predictive marker of reaction.Our results confirm the worth of maintaining angiogenesis inhibition with FOLFIRI-aflibercept in mCRC after development to a first-line treatment with bevacizumab. The development of high blood pressure during treatment is a possible predictive ma
Like
Comment
Share
